Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Nutritional status and the performance of multiple bedside tools for nutrition assessment among patients waiting for liver transplantation: A Canadian experience.

Marr KJ, Shaheen AA, Lam L, Stapleton M, Burak K, Raman M.

Clin Nutr ESPEN. 2017 Feb;17:68-74. doi: 10.1016/j.clnesp.2016.10.003. Epub 2016 Nov 12.

PMID:
28361750
2.

Integration of Contrast-enhanced US into a Multimodality Approach to Imaging of Nodules in a Cirrhotic Liver: How I Do It.

Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR.

Radiology. 2017 Feb;282(2):317-331. doi: 10.1148/radiol.2016151732.

PMID:
28099108
3.

A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale.

Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, Ma M, Bailey RJ, Jayakumar S, Burak KW, Abraldes JG, Brisebois A, Ferguson T, Majumdar SR.

Am J Gastroenterol. 2016 Dec;111(12):1759-1767. doi: 10.1038/ajg.2016.303. Epub 2016 Aug 2.

PMID:
27481305
4.

Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada.

Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ.

Can J Gastroenterol Hepatol. 2016;2016:1329532. doi: 10.1155/2016/1329532. Epub 2016 Apr 3.

5.

STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?

Abraldes JG, Burak KW.

Hepatology. 2016 Jul;64(1):13-5. doi: 10.1002/hep.28537. Epub 2016 Apr 15. No abstract available.

PMID:
26946464
6.

Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients.

O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS.

Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):293-6. No abstract available.

7.

Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data.

Pang JX, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, Swain MG, Burak KW, Quan H, Myers RP.

BMC Gastroenterol. 2015 Sep 11;15:116. doi: 10.1186/s12876-015-0348-5.

8.

Making progress in the ethical treatment of medical trainees.

Busche K, Burak KW, Veale P, Coderre S, McLaughlin K.

Adv Health Sci Educ Theory Pract. 2016 Aug;21(3):711-8. doi: 10.1007/s10459-015-9617-x. Epub 2015 Jun 20.

PMID:
26092833
9.

Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada.

Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ.

Can J Gastroenterol Hepatol. 2015 Jun 15. pii: 16942. [Epub ahead of print] No abstract available.

PMID:
26076400
11.

Risk factors for mortality in patients with alcoholic hepatitis and assessment of prognostic models: A population-based study.

Pang JX, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, Swain MG, Burak K, Quan H, Myers RP.

Can J Gastroenterol Hepatol. 2015 Apr;29(3):131-8.

13.

Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid).

Jhaveri K, Cleary S, Audet P, Balaa F, Bhayana D, Burak K, Chang S, Dixon E, Haider M, Molinari M, Reinhold C, Sherman M.

AJR Am J Roentgenol. 2015 Mar;204(3):498-509. doi: 10.2214/AJR.13.12399. Review.

PMID:
25714278
14.

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.

Myers RP, Shah H, Burak KW, Cooper C, Feld JJ.

Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. Erratum in: Can J Gastroenterol Hepatol. 2015 Mar;29(2):68.

15.

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.

McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ.

Cancer. 2015 May 15;121(10):1620-7. doi: 10.1002/cncr.29227. Epub 2015 Jan 6.

16.

Mobile physician reporting of clinically significant events-a novel way to improve handoff communication and supervision of resident on call activities.

Nabors C, Peterson SJ, Aronow WS, Sule S, Mumtaz A, Shah T, Eskridge E, Wold E, Stallings GW, Burak KK, Goldberg R, Guo G, Sekhri A, Mathew G, Khera S, Montoya J, Sharma M, Paudel R, Frishman WH.

J Patient Saf. 2014 Dec;10(4):211-7. doi: 10.1097/PTS.0b013e31829952ff.

PMID:
25408999
17.

The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.

Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1262-9. doi: 10.1111/apt.12990. Epub 2014 Oct 13.

18.

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.

Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly LB.

Ann Hepatol. 2014 Sep-Oct;13(5):525-32.

19.

Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list.

Myers RP, Tandon P, Ney M, Meeberg G, Faris P, Shaheen AA, Aspinall AI, Burak KW.

Liver Int. 2014 Sep;34(8):1176-83. doi: 10.1111/liv.12373. Epub 2013 Nov 20.

PMID:
24256642
20.

Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.

Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP.

Can J Gastroenterol. 2013;27(5):273-80. Erratum in: Can J Gastroenterol. 2013 Jun;27(6):376. Santodomino-Garzon, Tania [corrected to Santodomingo-Garzon, Tania].

Supplemental Content

Loading ...
Support Center